



REMARKS

The specification has been amended to include SEQ ID numbers which were omitted at the time of filing. Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 220002054822. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,



Susan B. Lynch
Registration No. (51,979)

Dated: October 10, 2002

By:

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7912
Facsimile: (858) 720-5125



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

RECEIVED

OCT 17 2002

TECH CENTER 1600/2900

Paragraph [24] at page 7 has been amended as follows:

As used herein, "isolated" refers to a state wherein the "isolated" material is removed from its natural surroundings. It may or may not be purified when it is isolated, but at least some of the components with which it is naturally associated have been removed or replaced.

Table 1

Peptide	Sequence
LAP	AALEAKICHQIEYYFGDF (<u>SEQ ID NO:1</u>)
702	AALEAQICQQI E YYFGDF (<u>SEQ ID NO:2</u>)
701	AALQAKICHQI E YYFGQF (<u>SEQ ID NO:3</u>)
761	QQQEAKICHQ I EYYFGDF (<u>SEQ ID NO:4</u>)
762	QQQE K QKCHQ I EYYFGDF (<u>SEQ ID NO:5</u>)
703	AALEAKICHQIEQQGDQ (<u>SEQ ID NO:6</u>)
771	AALEAKICHQIEYYQGDQ (<u>SEQ ID NO:7</u>)
772	AALEAKICHQIEQQFGDF (<u>SEQ ID NO:8</u>)
631	AALEAKICHQIEYYFGDQ (<u>SEQ ID NO:9</u>)
632	AALEAKICHQIEYYQGDF (<u>SEQ ID NO:10</u>)
741	AALEAKICHQIEQYFGDF (<u>SEQ ID NO:11</u>)
633	AALEAKICHQIEYQFGDF (<u>SEQ ID NO:12</u>)
MOUSE	ALEAKICHQIEYYFGDF (<u>SEQ ID NO:13</u>)
BOVINE	AALEAKICHQIEYYFGDF (<u>SEQ ID NO:14</u>)
XENOPUS	LDLDTKICEQIEYYFGDF (<u>SEQ ID NO:15</u>)
RAT	AALEAKICHQIEEYYFGDF (<u>SEQ ID NO:16</u>)
C. ELEGANS	DDADQR I KQLEYYYFGNI (<u>SEQ ID NO:17</u>)
MOSQUITO	VSKLEASTIRQ E YYFGDA (<u>SEQ ID NO:18</u>)
DROSOPHILA	QERAII R QVEYYFGDF (<u>SEQ ID NO:19</u>)

Paragraph [62] at page 16 has been amended as follows:

In general, the results showed that the ability of the peptides to enter and be retained in the cells paralleled their activity to inhibit translation. A summary of the results for the various peptides tested is shown in Table 2.

Peptide	Mutation	Activity	Cell Entry
LAP	AALEAKICHQIEYYFGDF (<u>SEQ ID NO:1</u>)	+	+++
702	AALEAQICQQIEYYFGDF (<u>SEQ ID NO:2</u>)	+	+++
701	AALQAKICHQIQYYFGQF (<u>SEQ ID NO:3</u>)	-	+
761	QQQEAKICHQIEYYFGDF (<u>SEQ ID NO:4</u>)	+	+
762	QQQEQQKQCHQIEYYFGDF (<u>SEQ ID NO:5</u>)	-	-
703	AALEAKICHQIEQQQGDQ (<u>SEQ ID NO:6</u>)	-	-
771	AALEAKICHQIEYYQGDQ (<u>SEQ ID NO:7</u>)	-	-
772	AALEAKICHQIEQQFGDF (<u>SEQ ID NO:8</u>)	-	-
741	AALEAKICHQIEQYFGDF (<u>SEQ ID NO:11</u>)	-	-
633	AALEAKICHQIEYQFGDF (<u>SEQ ID NO:12</u>)	+	+++
632	AALEAKICHQIEYYQGDF (<u>SEQ ID NO:10</u>)	-	-

In the Claims:

10. (Amended) The compound of claim 1 which is selected from the group consisting of AALEAQICQQIEYYFGDF (SEQ ID NO:2), AALQAKICHQIQYYFGQF (SEQ ID NO:3), QQQEAKICHQIEYYFGDF (SEQ ID NO:4) and AALEAKICHQIEYQFGDF (SEQ ID NO:12).

11. (Amended) The compound of claim 1 which is in isolated or purified form and is selected from the group consisting of ALEAKICHQIEYYFGDF (SEQ ID NO:13), AALEAKICHQIEYYFGDF (SEQ ID NO:14), LDLDTKICEQIEYYFGDF (SEQ ID NO:15),

AALAEAKICHQIEEYYFGDF (SEQ ID NO:16), DDADQRRIIKQLEYYFGNI (SEQ ID NO:17),
VSKLEASTIRQEYYFGDA (SEQ ID NO:18) and QERAIIRQVEYYFGDF (SEQ ID NO:19).

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

RECEIVED

OCT 17 2002

Applicant Must Provide:

TECH CENTER 1600/2900

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY